title: Levemopamil injection after cerebral oligemia reduces spatial memory deficits in rats.
abstract: Transient reduction of cerebral blood flow to oligemic levels as produced by bilateral clamping of carotid arteries (BCCA) in pentobarbital anesthetized Wistar rats leads to spatial orientation deficiencies in a water maze test 8-10 days after surgery. These deficiencies are more pronounced in 4-month-old than in 6-week-old animals. Levemopamil [(2S)-2-isopropyl-5-(methylphenethylamino)-2-phenylvaleronitril e hydrochloride], a Ca2+ channel blocker and 5-HT2 antagonist, prevents the deficiencies in groups of animals of both ages, even when administered 24 h after the transient vessel occlusion. Levemopamil did not influence the maze performance of sham-operated control rats. Levemopamil, therefore, appears to modulate mechanisms that are altered specifically either by, or as a consequence of, the BCCA procedure. Levemopamil did not influence the altered GABA or ACh content in different vulnerable brain structures following BCCA, showing that the substance acts via additional mechanisms affected by the BCCA procedure.
authors.affiliation: Department of Psychiatry, University of Göttingen, Germany.
authors.forename: C
authors.initials: C
authors.lastname: Heim
authors.forename: M
authors.initials: M
authors.lastname: Sieklucka
authors.forename: K H
authors.initials: KH
authors.lastname: Sontag
mesh_terms: D000109:Acetylcholine / Q000378:metabolism; D000818:Animals; D001923:Brain Chemistry / Q000187:drug effects / Q000502:physiology; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D002339:Carotid Arteries / Q000502:physiology; D002546:Ischemic Attack, Transient / Q000150:complications / Q000523:psychology*; D008297:Male; D018782:Maze Learning / Q000187:drug effects; D008569:Memory Disorders / Q000209:etiology / Q000517:prevention & control*; D051381:Rats; D017208:Rats, Wistar; D012702:Serotonin Antagonists / Q000627:therapeutic use*; D013028:Space Perception / Q000187:drug effects*; D014700:Verapamil / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005680:gamma-Aminobutyric Acid / Q000378:metabolism
chemical_list: D002121:Calcium Channel Blockers; D012702:Serotonin Antagonists; D005680:gamma-Aminobutyric Acid; D014700:Verapamil; C052752:emopamil; D000109:Acetylcholine